Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australia has led the world in the research and development of this scan using a relatively novel radiotracer, known as PSMA PET/CT. The availability of funding for PSMA PET/CT scans is a major win for patients, who until now have either paid for these tests themselves or found the scans unobtainable because of the cost. The Australasian Association of Nuclear Medicine Specialists (AANMS) welcomed the MBS funding which it says will help improve outcomes for thousands of men with a higher risk prostate cancer. “PSMA PET/CT imaging enables highly specific detection of tumour sites throughout the body with far greater sensitivity compared to other conventional scans. This enables doctors to make more accurate
diagnoses than is currently possible with other MBS-funded scans, and which in turn can be lifesaving for some patients,” said AANMS President, Associate Professor Sze Ting Lee.
The AANMS has worked closely with partners to achieve this important milestone in the diagnosis and treatment of prostate cancer.
“We would like to acknowledge the work of Dr Robert Ware from Cyclotek in generating the original funding application and their ongoing support in steering the application with AANMS during the tenure of my predecessor, Dr Geoff Schembri. We also extend our thanks to all those who supported the application, including AstraZeneca who sponsored the submission,” Associate Professor Lee said.
With funding now available, AANMS will work closely with other key stakeholders to ensure that patients are appropriately referred for these tests.
Australian Health Journal spoke with Associate Professor Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
About AANMS
The AANMS is a peak body representing medical practitioners working in the field of nuclear medicine diagnosis and therapy. It works to promote and advance the clinical practice of nuclear medicine, which can be used to both diagnose and treat patients with a range of health conditions including the leading causes of death in Australia; cancer, dementia, heart and lung diseases; as well as renal, endocrine and paediatric disorders. Together with government and other stakeholders, AANMS is working to build a strong and sustainable nuclear medicine sector in Australia in order to optimise health outcomes for Australia patients.
-
Message from former Australian Health Minister Hon Greg Hunt
The Honourable Greg Hunt served in the Australian Government as Minster for Health and Aged Care from 2017, previously as Industry, Innovation and Science Minister and before that the Environment Minister.
Elected as the Member for Flinders in 2001, Greg announced his retirement from politics late 2021 and in 2022, ahead of the Federal Election, having completed 20 years as a public servant.
Australian Health Journal recently caught up with Greg in a relaxed interview at his home in the Mornington Peninsula, Victoria to hear how a 9 month sabbatical has allowed him to focus on family, fitness and future. This has even included some “brutal spin cycle classes!”.
-
Integrating oral health care across non-dental professionals
Poor oral health can contribute to or exacerbate several systemic health conditions due to the close connection between oral bacteria, inflammation, and systemic processes. These conditions include cardiovascular health, diabetes, respiratory health, cognitive health, pregnancy and birth outcomes.
-
Health-Tech Connections
Challenges in health care delivery have compounded, with clinical staff being exposed to the Omicron COVID variant. Reduced staffing has brought on its challenges to most already-strained state health care systems and the people working in them.
However, over the past 2 years of the pandemic, technology has played an increasing role on the front end for patients and consumers at home and clinicians in the medical setting. Much more is planned in technology that will deliver efficiency, reduce risk and make available new models of care. This has the potential to touch the working lives of all stakeholders and
recipients of care.
